• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 9:44:29 AM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $TBIO alert in real time by email
    SC 13G/A 1 form-sc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934 (Amendment No.  1  )*

     

    Translate Bio, Inc.

     

    (Name of Issuer)

     

    Common Stock

     

    (Title of Class of Securities)

     

    89374L104

     

    (CUSIP Number)

     

    December 31, 2020

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X] Rule 13d-1(b)

     

    [  ] Rule 13d-1(c)

     

    [  ] Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 89374L104  

     

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      RTW Investments, LP
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
          (a) [  ]
          (b) [X]
       
    3. SEC USE ONLY
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware, United States of America
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
       
    5. SOLE VOTING POWER
       
      0 
       
    6. SHARED VOTING POWER
       
     

    2,978,427*

       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
     

    2,978,427*

       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     

    2,978,427*

       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
          [  ]
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     

    4.01%*

       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      PN, OO, IA

     

     
     

     

    CUSIP No. 89374L104  

     

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      Roderick Wong
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
          (a) [  ]
          (b) [X]
           
    3. SEC USE ONLY
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      United States of America
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
       
    5. SOLE VOTING POWER
       
      0
       
    6. SHARED VOTING POWER
       
     

    2,978,427*

       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
     

    2,978,427*

       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     

    2,978,427*

       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
          [  ]
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     

    4.01%

       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      IN, HC

     

     
     

     

    Item 1. (a).

    Name of Issuer:

     

    Translate Bio, Inc.

         
         
      (b). Address of issuer’s principal executive offices:
         
       

    29 Hartwell Avenue

       

    Lexington, MA 02421

         
         
    Item 2. (a). Name of person filing:
         
        RTW Investments, LP
        Roderick Wong
         
         
      (b). Address or principal business office or, if none, residence:
         
        RTW Investments, LP
        40 10th Avenue
        Floor 7
        New York, New York 10014
         
        Roderick Wong
        c/o RTW Investments, LP
       

    40 10th Avenue

        Floor 7
        New York, New York 10014
         
         
      (c). Citizenship:
         
        RTW Investments, LP – Delaware
        Roderick Wong – United States of America
         
         
      (d). Title of class of securities:
         
        Common Stock
         
         
      (e). CUSIP No.:
         
        89374L104
         

     

     
     

     

    Item 3. If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
           
      RTW Investments, LP:
           
      (a) [  ] Broker or Dealer Registered Under Section 15 of the Act (15 U.S.C. 78o)
      (b) [  ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)
      (c) [  ] Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c)
      (d) [  ] Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
      (e) [X] Investment Adviser in accordance with § 240.13d-1(b)(1)(ii)(E)
      (f) [  ] Employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F)
      (g) [  ] Parent Holding Company or control person in accordance with §240.13d-1(b)(ii)(G)
      (h) [  ] Savings Association as defined in §3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)
      (i) [  ] Church plan that is excluded from the definition of an investment company under §3(c)(15) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
      (j) [  ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J)
      (k) [  ] Group, in accordance with §240.13d-1(b)(ii)(K) (a) [_]
           
      Roderick Wong:
           
      (a) [  ] Broker or Dealer Registered Under Section 15 of the Act (15 U.S.C. 78o)
      (b) [  ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)
      (c) [  ] Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c)
      (d) [  ] Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
      (e) [  ] Investment Adviser in accordance with § 240.13d-1(b)(1)(ii)(E)
      (f) [  ] Employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F)
      (g) [X] Parent Holding Company or control person in accordance with §240.13d-1(b)(ii)(G)
      (h) [  ] Savings Association as defined in §3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)
      (i) [  ] Church plan that is excluded from the definition of an investment company under §3(c)(15) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
      (j) [  ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J)
      (k) [  ] Group, in accordance with §240.13d-1(b)(ii)(K) (a) [_]

     

    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
           
      (a)   Amount beneficially owned:
           
          RTW Investments, LP – 2,978,427*
          Roderick Wong – 2,978,427*
           
             
      (b)   Percent of class:
           
          RTW Investments, LP – 4.01%*
          Roderick Wong – 4.01%*
           
           
      (c)   Number of shares as to which the person has:
           
          (i) Sole power to vote or to direct the vote
             
            RTW Investments, LP – 0
            Roderick Wong – 0
             
          (ii) Shared power to vote or to direct the vote
             
            RTW Investments, LP – 2,978,427*
            Roderick Wong – 2,978,427*
             
          (iii) Sole power to dispose or to direct the disposition of
             
            RTW Investments, LP – 0
            Roderick Wong – 0
             
          (iv) Shared power to dispose or to direct the disposition of
             
            RTW Investments, LP – 2,978,427*
            Roderick Wong – 2,978,427*

     

     

    * The shares of common stock (the "Shares"), of Translate Bio, Inc. (the "Company"), reported herein are held by one or more private funds (together the "Funds"), which are managed by RTW Investments, LP (the "Adviser"). The Adviser, in its capacity as the investment manager of Funds, has the power to vote and the power to direct the disposition of all Shares held by the Funds. Accordingly, for the purposes of Reg. Section 240.13d-3, the Adviser may be deemed to beneficially own an aggregate of 2,978,427 Shares, or 4.01% of the Shares issued and outstanding as of November 2, 2020. Roderick Wong is the Managing Partner of the Adviser. The beneficial ownership percentage reported herein is based on 74,321,827 Shares issued and outstanding as of November 2, 2020, as disclosed in the Company's Form 10-Q Quarterly Report, as filed with the Securities and Exchange Commission on November 5, 2020. This report shall not be deemed an admission that the Adviser, the Funds or any other person is the beneficial owner of the securities reported herein for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the reporting persons herein disclaims beneficial ownership of the Shares reported herein except to the extent of the reporting person’s pecuniary interest therein.

     

     
     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

       
      [X]
       
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

       
      N/A
       
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
     

    If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

       
      N/A
       
       
    Item 8. Identification and Classification of Members of the Group.
       
     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

       
      N/A
       
       
    Item 9. Notice of Dissolution of Group.
       
     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

       
      N/A
       
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 12, 2021    
         
      RTW Investments, LP
         
      By: /s/ Roderick Wong
        Roderick Wong, Managing Partner
         
      Roderick Wong
         
      By: /s/ Roderick Wong
        Roderick Wong, Individually

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

    Get the next $TBIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TBIO

    DatePrice TargetRatingAnalyst
    8/4/2021$45.00 → $38.00Neutral
    Roth Capital
    8/3/2021$19.00 → $38.00Market Perform
    SVB Leerink
    8/3/2021Outperform → Market Perform
    William Blair
    7/26/2021$28.00 → $45.00Buy
    Roth Capital
    More analyst ratings

    $TBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Krueger Todd was granted 8,390 shares (SEC Form 4)

    4 - Telesis Bio Inc. (0001850079) (Issuer)

    7/26/24 4:07:04 PM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Golub Steven J was granted 8,390 shares (SEC Form 4)

    4 - Telesis Bio Inc. (0001850079) (Issuer)

    7/26/24 4:06:35 PM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Hlavinka Sarah E. was granted 8,390 shares (SEC Form 4)

    4 - Telesis Bio Inc. (0001850079) (Issuer)

    7/26/24 4:06:03 PM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

    New technology has potential to accelerate timelines for therapeutic research and drug development Telesis Bio Inc. (OTC:TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced a new license agreement with Regeneron Pharmaceuticals, Inc. to deploy Telesis Bio's revolutionary Gibson SOLA™ platform at its R&D core facilities. This will help Regeneron adopt automated, high-throughput, on-demand gene synthesis in their own labs. Using Gibson SOLA at scale is intended to contribute to an agile and efficient approach to biologics discovery. The Gibson SOLA platform has been shown to e

    5/28/25 9:00:00 AM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis

    Telesis Bio, a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced that it has entered into a convertible preferred stock purchase agreement (the Purchase Agreement) to sell shares of a new series of convertible preferred stock in a private placement. The financing was led by Novalis LifeSciences and Northpond Ventures and is expected to result in gross proceeds to the Company of up to approximately $21 million. The Company's recently launched proprietary next-generation enzymatic synthesis platform, Gibson SOLA™, allows customers to take full control of their nucleic acid supply-chain,

    3/18/25 9:00:00 AM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis

    SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- A new partnership between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, will create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesis of DNA. This innovative approach enabled by Telesis Bio's Gibson SOLA enzymatic reagent platform running on Beckman Coulter Life Sciences automation to ensures rapid, reliable, and highly scalable production of extremely high-fidelity DNA, empowering researchers to achieve greater productivity and innovation in a wide array of discovery applications. The collaboration integrates Telesis Bio's Gibson

    9/25/24 4:05:00 PM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TBIO
    SEC Filings

    View All

    SEC Form 15-12G filed by Telesis Bio Inc.

    15-12G - Telesis Bio Inc. (0001850079) (Filer)

    1/14/25 4:35:26 PM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form EFFECT filed by Telesis Bio Inc.

    EFFECT - Telesis Bio Inc. (0001850079) (Filer)

    1/7/25 12:15:02 AM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form EFFECT filed by Telesis Bio Inc.

    EFFECT - Telesis Bio Inc. (0001850079) (Filer)

    1/7/25 12:15:03 AM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital reiterated coverage on Translate Bio with a new price target

    Roth Capital reiterated coverage of Translate Bio with a rating of Neutral and set a new price target of $38.00 from $45.00 previously

    8/4/21 10:08:32 AM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SVB Leerink reiterated coverage on Translate Bio with a new price target

    SVB Leerink reiterated coverage of Translate Bio with a rating of Market Perform and set a new price target of $38.00 from $19.00 previously

    8/3/21 11:37:09 AM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Translate Bio downgraded by William Blair

    William Blair downgraded Translate Bio from Outperform to Market Perform

    8/3/21 11:20:22 AM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TBIO
    Financials

    Live finance-specific insights

    View All

    Telesis Bio Reports First Quarter 2024 Financial Results

    SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the first quarter of 2024.  In discussing results, recently appointed President and CEO Eric Esser said, "I am pleased with our performance as we execute against our strategy to focus on Gibson SOLA and BioXp mRNA solutions. Our BioXp mRNA offerings continue to gain traction and are delivering real improvements in speed and simplicity to our customers in their discovery workflows. I'm also excited abo

    5/9/24 4:05:00 PM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results

    SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023. Results highlight strong BioXp® kit sales, expanding gross margin and reduced operating expense. In discussing the results, Todd R. Nelson Ph.D., Founder and CEO of Telesis Bio said, "I'm pleased with our operating execution in a challenging macro environment during 2023. Our company experienced record BioXp kits sales and expanding gross margin aga

    3/28/24 4:05:00 PM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Telesis Bio Reports Third Quarter 2023 Financial Results

    SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023. "This quarter, we continued to drive adoption of our instruments and kits, make progress against important collaborations, advance our mRNA strategy, and strengthen both our Board of Directors and Management Team," said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. Highlights Strengthened board of directors and management team: Appointed Greg Herrema, Senior Advisor to Novalis LifeSciences to the Telesis Bio board of directors in October 2023. Mr. Herrema's distinguished car

    11/13/23 4:22:00 PM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Telesis Bio Inc.

    SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)

    11/8/24 8:23:25 AM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13D/A filed by Telesis Bio Inc.

    SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)

    11/6/24 4:50:27 PM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13D/A filed by Telesis Bio Inc.

    SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)

    11/6/24 4:05:27 PM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Telesis Bio Reports Second Quarter and First Half 2024 Financial Results

    SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, today announced financial results for the second quarter and first half of 2024. Highlights Gibson SOLA – the Company continues to advance its Gibson SOLA reagent platform that enables on-premises automated overnight synthesis of high-fidelity long DNA and mRNA on a variety of liquid handling platforms. The Company's presentation "Enhancing Therapeutic Protein Production with Gibson SOLA Enzymatic DNA Assembly: Pioneeri

    8/7/24 4:05:00 PM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Vicore Expands and Strengthens its Board of Directors

    STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

    5/14/24 2:20:00 AM ET
    $KRON
    $MACK
    $MXCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Biotechnology: Laboratory Analytical Instruments

    Telesis Bio Appoints William J. Kullback Chief Financial Officer

    SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial Officer, effective August 28, 2023. As CFO, Kullback will be responsible for the Company's financial planning and analysis, accounting, internal audit, tax, and treasury functions. "Bill's deep industry knowledge, operational expertise, and extensive financial experience make him ideally positioned to help lead us through the next phase of the Company's growth," said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. "We are thrilled to welcome Bill to our team and excited to have another lead

    8/29/23 4:05:00 PM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials